CTRI/2008/091/000004已完成1 期
An Open Label, Multicenter Phase I/II Study To Evaluate Safety and Efficacy of P276-00 in Subjects with Relapsed and/or Relapsed/Refractory Multiple Myeloma
Piramal Life Science0 个研究点目标入组 26 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects previously diagnosed with multiple myeloma based either on the standard diagnostic criteria or the International Myeloma Foundation (IMF) diagnostic criteria
- •Subjects must have relapsed and/or relapsed/refractory disease after at least 2 prior lines of therapy
- •Monoclonal protein in the serum of greater than or equal to 1 g/dL or monoclonal light chain in the urine protein electrophoresis of greater than or equal to 200 mg/ 24 hours, or measurable light chains by free light chain assay of greater than or equal to 10 mg/dL, or measurable plasmacytoma
- •Age greater than or equal to18 years
- •ECOG performance status less than or equal to 2
- •Life expectancygreater than or equal to 3 months
- •Hemoglobin greater than or equal to8.0 gm/dL
- •Absolute Neutrophil Count (ANC) greater than or equal to1000 cells/mm3
- •Platelets countgreater than or equal to 50,000/mm3
- •SGOT/AST less than 3.0 x institutional upper limits of normal
- •Serum SGPT/ALT less than 3.0 x institutional upper limits of normal
- •Serum creatinine less than 2.5mg/dL
- •Serum total bilirubin less than 1.5 x institutional upper limits of normal
- •Woman of childbearing potential with a negative serum pregnancy test. In addition, all sexually active woman of childbearing potential and men agreeing to use adequate contraception prior to study entry, during the duration of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilised.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Subjects having received radiotherapy, immunotherapy, chemotherapy and/or biological agents like G-CSF in the 4 weeks prior to day 1 of study drug administration or have not recovered (grade less than or equal to 1) from adverse effects of such therapy received prior to 4 weeks
- •Subjects having received any other investigational agents within 4 weeks prior to the date of enrolment or have not recovered from adverse effects of the investigational agent received prior to 4 weeks.
- •History of allergic reactions attributed to compounds of similar chemical composition to P276-00.
- •Subjects with a history of myocardial infarction or uncontrolled cardiac dysfunction during the previous 6 months.
- •Prior malignancy (within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been disease-free for at least 3 years.
- •Subjects with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, cardiac ejection fraction 40%, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Women who are pregnant or nursing
- •Subjects known to be seropositive for the human immunodeficiency virus or any history or evidence from physical examination of HIV infection.
- •Subjects requiring the use of concomitant medications that prolong the QT/QTc interval and/or are known to cause Torsades de Pointes (TdP).
研究者
相似试验
尚未招募
2 期
An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with MelanomaCancer - Malignant melanomaAdvanced MelanomaACTRN12606000330549Solbec Pharmaceuticals Ltd56
尚未招募
2 期
An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with Renal Cell CarcinomaAdvanced Renal Cell CarcinomaCancer - Renal Cell CarcinomaACTRN12606000099527Solbec Pharmaceuticals Ltd56
进行中（未招募）
1 期
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 5-6, in 1st line systemic therapy.EUCTR2009-011925-14-ATBoehringer Ingelheim RCV GmbH & Co. KG132
进行中（未招募）
1 期
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)EUCTR2009-011925-14-DEBoehringer Ingelheim Pharma GmbH & Co. KG132
进行中（未招募）
1 期
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)EUCTR2009-011925-14-NLBoehringer Ingelheim bv132